

# Matthew J Price

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6172308/publications.pdf>

Version: 2024-02-01

218  
papers

17,290  
citations

34105

52  
h-index

14208

128  
g-index

255  
all docs

255  
docs citations

255  
times ranked

12286  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1â€month dual antiplatelet therapy following <scp>PCI</scp>: Analysis from the <scp>Onyx ONE</scp> clear study. Catheterization and Cardiovascular Interventions, 2022, 99, 583-592.	1.7	3
2	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120010390.	3.9	4
3	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: Aâ€Patient-Level Analysis of the Disrupt CAD Studies. , 2022, 1, 100011.		3
4	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011069.	3.9	0
5	Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States. JACC: Cardiovascular Interventions, 2022, 15, 741-750.	2.9	19
6	Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAO Registry. Circulation: Cardiovascular Interventions, 2022, 15, .	3.9	14
7	Letter by Price et al Regarding the Article, â€œAmplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trialâ€ Circulation, 2022, 145, e849.	1.6	0
8	Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC: Cardiovascular Interventions, 2022, 15, 950-961.	2.9	11
9	Antithrombotic Therapy After Leftâ€Atrialâ€Appendage Occlusion in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1785-1798.	2.8	42
10	Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients. JACC: Cardiovascular Interventions, 2022, 15, 1153-1163.	2.9	10
11	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
12	Primary Results of the EVOLVE Short DAPT Study. Circulation: Cardiovascular Interventions, 2021, 14, e010144.	3.9	48
13	Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions. JACC: Cardiovascular Interventions, 2021, 14, 1337-1348.	2.9	66
14	Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention â€“ Insights from the CHAMPION program. American Heart Journal Plus, 2021, 9, 100043.	0.6	0
15	Treatment and Outcomes of Device-Related Thrombus After Transcatheter Left Atrial Appendage Closure. Circulation: Cardiovascular Interventions, 2021, 14, e010889.	3.9	1
16	Risk of thromboembolic events after percutaneous left atrial appendage ligation in patients with atrial fibrillation: Long-term results of a multicenter study. Heart Rhythm, 2020, 17, 175-181.	0.7	38
17	Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients. Interventional Cardiology Clinics, 2020, 9, 441-449.	0.4	0
18	Intravascular Lithotripsy for Treatment of Severely Calcified Coronaryâ€Artery Disease. Journal of the American College of Cardiology, 2020, 76, 2635-2646.	2.8	209

#	ARTICLE	IF	CITATIONS
19	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009565.	3.9	49
20	Use of a Novel Septal Occluder Device for Left Atrial Appendage Closure in Patients With Postsurgical and Postlariat Leaks or Anatomies Unsuitable for Conventional Percutaneous Occlusion. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009227.	3.9	11
21	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008603.	3.9	28
22	Diagnostic Accuracy of Nonhyperemic Pressure Ratios Using a Pressure Sensing Microcatheter. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1272-1275.	2.9	1
23	Transcatheter Left Atrial Appendage Occlusion in the DOAC Era. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3136-3139.	2.8	7
24	A Pilot Study of Monotherapy with a Non-Vitamin K-Antagonist Oral Anticoagulant following Watchman Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation. <i>Structural Heart</i> , 2020, 4, 288-292.	0.6	2
25	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 606-617.	2.9	90
26	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020, 382, 1208-1218.	27.0	207
27	The NCDR Left Atrial Appendage Occlusion Registry. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1503-1518.	2.8	237
28	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007342.	3.9	10
29	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019, 42, 797-805.	1.8	4
30	Transcatheter Edge-to-Edge Repair for Primary (Degenerative) Mitral Regurgitation. <i>Interventional Cardiology Clinics</i> , 2019, 8, 245-259.	0.4	3
31	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	2.9	366
32	Transcatheter Mitral Valve Repair and Replacement: New Standards of Care and New Horizons for Therapy. <i>Interventional Cardiology Clinics</i> , 2019, 8, xi-xii.	0.4	0
33	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1-month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019, 214, 134-141.	2.7	31
34	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	2.2	335
35	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
36	Device-Related Thrombus After Transcatheter Left Atrial Appendage Closure. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1015-1017.	2.9	3

#	ARTICLE	IF	CITATIONS
37	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y <sub>12</sub> Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007445.	3.9	0
38	EFFECT OF TRANSCATHETER MITRAL VALVE REPAIR ON HEART FAILURE MANAGEMENT AND PULMONARY ARTERY PRESSURES AS ASSESSED BY CARDIOMEMS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2003.	2.8	0
39	Percutaneous Coronary Intervention Gathers No Moss. <i>Interventional Cardiology Clinics</i> , 2019, 8, ix.	0.4	0
40	Newer-generation Metallic Stents. <i>Interventional Cardiology Clinics</i> , 2019, 8, 95-109.	0.4	4
41	Full Revascularization in the Patient With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2724-2727.	2.8	5
42	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019, 278, 217-222.	1.7	6
43	Thromboembolic events and need for anticoagulation therapy following left atrial appendage occlusion in patients with electrical isolation of the appendage. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 511-516.	1.7	21
44	The functional assessment of patients with non-obstructive coronary artery disease: expert review from an international microcirculation working group. <i>EuroIntervention</i> , 2019, 14, 1694-1702.	3.2	32
45	Current State of Left Atrial Appendage Closure. <i>Current Cardiology Reports</i> , 2018, 20, 42.	2.9	9
46	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005635.	3.9	13
47	Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2018, 71, 564-574.	2.8	40
48	Safety and Efficacy of Transcatheter Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 542-549.	3.1	7
49	Pharmacogenomic Testing to Select Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1878-1881.	2.8	6
50	The WATCHMAN Left Atrial Appendage Closure Device. <i>Interventional Cardiology Clinics</i> , 2018, 7, 201-212.	0.4	7
51	Left Atrial Appendage Occlusion. <i>Interventional Cardiology Clinics</i> , 2018, 7, 159-168.	0.4	4
52	Percutaneous closure of patent foramen ovale vs. medical treatment for patients with history of cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 852-858.	0.8	15
53	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 158-165.	1.0	7
54	Cangrelor compared with clopidogrel in patients with prior myocardial infarction â€œ Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 250, 49-55.	1.7	5

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial. Catheterization and Cardiovascular Interventions, 2018, 92, 253-259.	1.7	26
56	Left Atrial Appendage Therapies. , 2018, , 473-487.		0
57	TCT-841 Baseline characteristics and 3-month outcomes of the EVOLVE Short DAPT Trial: A prospective investigation of abbreviated antiplatelet therapy in high bleeding risk patients treated with a thin-strut bioabsorbable polymer-coated, everolimus-eluting coronary stent. Journal of the American College of Cardiology, 2018, 72, B335-B336.	2.8	0
58	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. European Heart Journal, 2018, 39, 4112-4121.	2.2	49
59	Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y <sub>12</sub> Receptor Inhibiting Therapies" Circulation, 2018, 137, 2310-2311.	1.6	2
60	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2018, 138, 527-536.	1.6	211
61	New Volumetric Analysis Method for Stent Expansion and its Correlation With Final Fractional Flow Reserve and Clinical Outcome. JACC: Cardiovascular Interventions, 2018, 11, 1467-1478.	2.9	34
62	Imaging in Intervention. Interventional Cardiology Clinics, 2018, 7, xi.	0.4	0
63	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. American Heart Journal, 2018, 205, 110-117.	2.7	22
64	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. International Journal of Cardiology, 2018, 270, 96-101.	1.7	10
65	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention, 2018, 13, e1841-e1849.	3.2	16
66	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheterization and Cardiovascular Interventions, 2017, 89, 190-198.	1.7	18
67	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	2.8	47
68	Synthesis and Characterization of 2-Phenylimidazo[1,2-a]pyridine: A Privileged Structure for Medicinal Chemistry. Journal of Chemical Education, 2017, 94, 388-391.	2.3	8
69	ANTARCTIC: platelet function testing to adjust therapy. Lancet, The, 2017, 389, 1193.	13.7	3
70	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. JAMA Cardiology, 2017, 2, 127.	6.1	36
71	Cangrelor. Interventional Cardiology Clinics, 2017, 6, 39-47.	0.4	5
72	TWELVE MONTH FOLLOW-UP DATA FROM THE ONYX CORE TRIAL: ANGIOGRAPHIC AND CLINICAL PERFORMANCE OF NEXT GENERATION RESOLUTE ONYX DRUG-ELUTING STENT. Journal of the American College of Cardiology, 2017, 69, 1110.	2.8	0

#	ARTICLE	IF	CITATIONS
73	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. American Heart Journal, 2017, 188, 147-155.	2.7	2
74	Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2017, 6, xi-xii.	0.4	0
75	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	6
76	International Expert Consensus on Switching Platelet P2Y <sub>12</sub> Receptor-Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
77	Imaging Assessment of the Interatrial Septum for Transcatheter Atrial Septal Defect and Patent Foramen Ovale Closure. Interventional Cardiology Clinics, 2017, 6, 505-524.	0.4	7
78	Transcatheter Closure of Patent Foramen Ovale. Interventional Cardiology Clinics, 2017, 6, ix-x.	0.4	1
79	Transcatheter Closure of Patent Foramen Ovale. Interventional Cardiology Clinics, 2017, 6, 555-567.	0.4	8
80	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462	1.6	12
81	First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. JACC: Cardiovascular Interventions, 2017, 10, 1381-1388.	2.9	50
82	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	7
83	5-Year Outcomes After Left Atrial Appendage Closure. Journal of the American College of Cardiology, 2017, 70, 2964-2975.	2.8	725
84	Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm, 2017, 14, 19-24.	0.7	96
85	Assessing the Safety of Early U.S. Commercial Application of Left Atrial Appendage Closure. Journal of the American College of Cardiology, 2017, 69, 262-264.	2.8	10
86	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 2017, 117, 1093-1100.	3.4	9
87	ACIST-FFR Study (Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional) Tj ETQq1 1 0.784314 rgBT /Over	3.9	37
88	IMPACT OF PRIOR CEREBROVASCULAR EVENTS ON ISCHEMIC AND BLEEDING OUTCOMES WITH CANGRELOR IN PERCUTANEOUS CORONARY INTERVENTION. Journal of the American College of Cardiology, 2016, 67, 198.	2.8	0
89	Cardiovascular Interventions in the Modern Age. JACC: Cardiovascular Interventions, 2016, 9, 1083-1084.	2.9	0
90	Off-Hours Versus On-Hours Presentation in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 2385-2387.	2.8	6

#	ARTICLE	IF	CITATIONS
91	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. <i>Circulation</i> , 2016, 134, 723-733.	1.6	31
92	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	2.9	38
93	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	83
94	The Pharmacodynamics of Switching Between P2Y12 Receptor Antagonists. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1099-1101.	2.9	1
95	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	10
96	Clinical Implications of Leaks Following Left Atrial Appendage Ligation With the LARIAT Device. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1051-1057.	2.9	45
97	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26
98	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	2.8	25
99	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 374-383.	2.1	32
100	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016, 37, 1122-1130.	2.2	23
101	WATCHMAN: Trials and Registries Results. <i>Contemporary Cardiology</i> , 2016, , 169-180.	0.1	0
102	Catheter-Based Left Atrial Appendage Closure. , 2016, , 107-117.		0
103	A review of the LARIAT device: insights from the cumulative clinical experience. <i>SpringerPlus</i> , 2015, 4, 522.	1.2	22
104	Randomized Controlled Trial of Home-Based Telehealth Versus In-Person Prolonged Exposure for Combat-Related PTSD in Veterans: Preliminary Results. <i>Journal of Clinical Psychology</i> , 2015, 71, 500-512.	1.9	110
105	Left atrial appendage closure—facing the truth and forging the future. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 313-314.	1.7	0
106	Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1925-1932.	2.9	84
107	Risk Assessment in Patient Selection for Transcatheter Aortic Valve Replacement. <i>Interventional Cardiology Clinics</i> , 2015, 4, 1-12.	0.4	4
108	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 405-406.	2.8	1



#	ARTICLE	IF	CITATIONS
109	Impingement of Left Main Ostium After Device Occlusion of Paravalvular Leak Post-Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, e1-e2.	2.9	0
110	Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. European Heart Journal, 2015, 36, 3346-3355.	2.2	197
111	Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 2614-2623.	2.8	470
112	AN INVESTIGATION OF OUTCOME EXPECTANCIES AS A PREDICTOR OF TREATMENT RESPONSE FOR COMBAT VETERANS WITH PTSD: COMPARISON OF CLINICIAN, SELF-REPORT, AND BIOLOGICAL MEASURES. Depression and Anxiety, 2015, 32, 392-399.	4.1	27
113	Bleeding and stent thrombosis on P2Y <sub>12</sub> -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	2.2	297
114	Update on the Guidelines for the Management of ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 115, 3A-9A.	1.6	14
115	A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. Journal of Thrombosis and Thrombolysis, 2015, 39, 8-14.	2.1	13
116	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. JACC: Cardiovascular Interventions, 2015, 8, 424-433.	2.9	35
117	The Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 65, 1311-1313.	2.8	4
118	Percutaneous Left Atrial Appendage Ligation for Stroke Prevention in Atrial Fibrillation. Methodist DeBakey Cardiovascular Journal, 2015, 11, 94-99.	1.0	1
119	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. Cardiovascular Revascularization Medicine, 2015, 16, 450-454.	0.8	12
120	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. Journal of Thrombosis and Thrombolysis, 2015, 40, 317-322.	2.1	26
121	TCT-75 Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial. Journal of the American College of Cardiology, 2015, 66, B35.	2.8	0
122	Safety and Efficacy of Cangrelor, an Intravenous, Short-Acting Platelet Inhibitor in Patients Requiring Coronary Artery Bypass Surgery. Heart Surgery Forum, 2015, 16, 60.	0.5	6
123	Cangrelor for treatment of arterial thrombosis. Expert Opinion on Pharmacotherapy, 2014, 15, 565-572.	1.8	4
124	Conversations in Cardiology. Catheterization and Cardiovascular Interventions, 2014, 83, 748-752.	1.7	1
125	Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. Journal of Thrombosis and Haemostasis, 2014, 12, 560-563.	3.8	4
126	Percutaneous management of late leak after lariat transcatheter ligation of the left atrial appendage in patients with atrial fibrillation at high risk for stroke. Catheterization and Cardiovascular Interventions, 2014, 83, 664-669.	1.7	35



#	ARTICLE	IF	CITATIONS
127	mHealth: A Mechanism to Deliver More Accessible, More Effective Mental Health Care. <i>Clinical Psychology and Psychotherapy</i> , 2014, 21, 427-436.	2.7	398
128	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 619-629.	2.8	92
129	Prevention and Management of Complications of Left Atrial Appendage Closure Devices. <i>Interventional Cardiology Clinics</i> , 2014, 3, 301-311.	0.4	8
130	Diabetes Mellitus and Clopidogrel Response Variability— <i>Journal of the American College of Cardiology</i> , 2014, 64, 1015-1018.	2.8	8
131	Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 565-572.	2.8	200
132	Left Atrial Appendage Closure to Prevent Stroke in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 202-212.	1.6	32
133	Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1-12.	2.8	1,605
134	Mechanical closure devices for atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 225-231.	4.9	2
135	Examination of Prior Experience with Telehealth and Comfort with Telehealth Technology as a Moderator of Treatment Response for PTSD and Depression in Veterans. <i>International Journal of Psychiatry in Medicine</i> , 2014, 48, 57-67.	1.8	35
136	Left Atrial Appendage Occlusion With the WATCHMAN <sup>®</sup> for Stroke Prevention in Atrial Fibrillation. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 142-151.	1.4	7
137	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	2.8	807
138	Platelet reactivity after coronary stenting. <i>Lancet</i> , The, 2013, 382, 583-584.	13.7	2
139	Platelet Function and Genetic Testing. <i>Journal of the American College of Cardiology</i> , 2013, 62, S21-S31.	2.8	28
140	Pharmacogenomics in Interventional Pharmacology. <i>Interventional Cardiology Clinics</i> , 2013, 2, 615-625.	0.4	2
141	Percutaneous Closure of Paravalvular Leak After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, e6-e8.	2.9	15
142	Platelet Function Monitoring and Clopidogrel. <i>Current Cardiology Reports</i> , 2013, 15, 321.	2.9	9
143	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	27.0	695
144	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2140-2148.	1.7	113

#	ARTICLE	IF	CITATIONS
145	The role of clopidogrel in the management of ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2013, 28, 381-388.	1.8	0
146	PREDICTORS OF COMPLETION OF EXPOSURE THERAPY IN OEF/OIF VETERANS WITH POSTTRAUMATIC STRESS DISORDER. <i>Depression and Anxiety</i> , 2013, 30, 1107-1113.	4.1	46
147	Retrospective multicenter observational study of the interventional management of coronary disease in the very elderly: The NINETY. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 414-421.	1.7	10
148	Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. <i>Thrombosis and Haemostasis</i> , 2013, 109, 808-816.	3.4	32
149	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 265-74.	7.4	386
150	Measured Drug Effect and Cardiovascular Outcomes in Patients Receiving Platelet P2Y <sub>12</sub> Receptor Antagonists. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1806.	7.4	7
151	Response to Letters Regarding Article, "Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y <sub>12</sub> Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial" <i>Circulation</i> , 2012, 125, .	1.6	1
152	Behavioral Activation and Therapeutic Exposure: An Investigation of Relative Symptom Changes in PTSD and Depression During the Course of Integrated Behavioral Activation, Situational Exposure, and Imaginal Exposure Techniques. <i>Behavior Modification</i> , 2012, 36, 580-599.	1.6	78
153	Left atrial appendage occlusion for the reduction of stroke and embolism in patients with atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 131-137.	1.5	3
154	Outcome expectancy as a predictor of treatment response in cognitive behavioral therapy for public speaking fears within social anxiety disorder.. <i>Psychotherapy</i> , 2012, 49, 173-179.	1.2	85
155	Prolonged exposure therapy for combat-related posttraumatic stress disorder: Comparing outcomes for veterans of different wars.. <i>Psychological Services</i> , 2012, 9, 16-25.	1.5	62
156	Genetic Considerations. <i>Advances in Cardiology</i> , 2012, 47, 100-113.	2.7	3
157	Symptom overlap in posttraumatic stress disorder and major depression. <i>Psychiatry Research</i> , 2012, 196, 267-270.	3.3	144
158	The effect of exercise absence on affect and body dissatisfaction as moderated by obligatory exercise beliefs and eating disordered beliefs and behaviors. <i>Psychology of Sport and Exercise</i> , 2012, 13, 500-508.	2.1	20
159	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012, 163, 768-776.e2.	2.7	72
160	Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1928-1937.	2.8	127
161	Left Main Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1605-1613.	2.8	26
162	Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2338-2343.	2.8	104

#	ARTICLE	IF	CITATIONS
163	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 44-55.	2.1	131
164	Mindfulness Moderates the Relationship Between Disordered Eating Cognitions and Disordered Eating Behaviors in a Non-Clinical College Sample. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2012, 34, 107-115.	1.2	55
165	Platelet Inhibitor Agents. , 2012, , 97-112.		2
166	Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, 1132-1137.	1.6	381
167	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1945-1954.	2.8	383
168	The impact of cognitive behavioral therapy on post event processing among those with social anxiety disorder. <i>Behaviour Research and Therapy</i> , 2011, 49, 132-137.	3.1	63
169	Psychological flexibility mediates the relations between self-concealment and negative psychological outcomes. <i>Personality and Individual Differences</i> , 2011, 50, 243-247.	2.9	49
170	Clinical outcomes following predilation with a novel 1.25â€mm diameter angioplasty catheter. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 510-514.	1.7	5
171	Functional testing methods for the antiplatelet effect of P2Y12receptor antagonists. <i>Biomarkers in Medicine</i> , 2011, 5, 43-51.	1.4	11
172	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1097.	7.4	1,185
173	Standard- vs High-Dose Clopidogrel After Percutaneous Coronary Interventionâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2520.	7.4	1
174	Platelet-Mediated Thrombosis and Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 629-637.	3.9	7
175	The Influence of CYP2C19 Polymorphisms on the Pharmacokinetics, Pharmacodynamics, and Clinical Effectiveness of P2Y12 Inhibitors. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 1-12.	1.4	24
176	The Brave New World of Antiplatelet Therapy: Seeking Clarity in a World of Increasing Choice and Complexity. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 1-3.	1.4	32
177	Utility of onâ€line threeâ€dimensional transesophageal echocardiography during percutaneous atrial septal defect closure. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 570-577.	1.7	16
178	Threeâ€year outcome of drugâ€eluting stent implantation for coronary artery bifurcation lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 309-314.	1.7	21
179	A novel technique for ultraâ€low contrast administration during angiography or intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 1076-1083.	1.7	52
180	Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1001-1007.	2.9	38

#	ARTICLE	IF	CITATIONS
181	The Evidence Base for Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 277-283.	3.9	10
182	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	2.8	1,058
183	IMPACT OF PLATELET REACTIVITY ON CLINICAL OUTCOMES: A PATIENT LEVEL META-ANALYSIS. <i>Journal of the American College of Cardiology</i> , 2010, 55, A179.E1673.	2.8	2
184	Bedside Evaluation of Thienopyridine Antiplatelet Therapy. <i>Circulation</i> , 2009, 119, 2625-2632.	1.6	118
185	Safety and Performance of Targeted Renal Therapy: The Be-RIte! Registry. <i>Journal of Endovascular Therapy</i> , 2009, 16, 1-12.	1.5	87
186	Monitoring Platelet Function to Reduce the Risk of Ischemic and Bleeding Complications. <i>American Journal of Cardiology</i> , 2009, 103, 35A-39A.	1.6	31
187	Relation of Periprocedural Bleeding Complications and Long-Term Outcome in Patients Undergoing Percutaneous Coronary Revascularization (from the Evaluation of Oral Xemilofiban in Controlling) <i>Tj ETQq1 1 0.784314 rgBT1/Overlook</i>	1.4	1
188	Predictors of Heightened Platelet Reactivity Despite Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2009, 103, 1339-1343.	1.6	138
189	Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1279-1285.	2.9	34
190	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009, 157, 818-824.e1.	2.7	110
191	The Role of Psychological Flexibility in Mental Health Stigma and Psychological Distress for the Stigmatizer. <i>Journal of Social and Clinical Psychology</i> , 2009, 28, 1244-1262.	0.5	50
192	Antiplatelet therapy in acute coronary syndromes. <i>Current Cardiology Reports</i> , 2008, 10, 327-333.	2.9	5
193	The off-versus on-label use of medical devices in interventional cardiovascular medicine: Clarifying the ambiguity between regulatory labeling and clinical decision-making, Part 1: PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 500-504.	1.7	8
194	Dynamics of Platelet Functional Recovery Following a Clopidogrel Loading Dose in Healthy Volunteers. <i>American Journal of Cardiology</i> , 2008, 102, 790-795.	1.6	28
195	Greater Expectations: Using Hierarchical Linear Modeling to Examine Expectancy for Treatment Outcome as a Predictor of Treatment Response. <i>Behavior Therapy</i> , 2008, 39, 398-405.	2.4	71
196	Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. <i>European Heart Journal</i> , 2008, 29, 992-1000.	2.2	593
197	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. <i>American Heart Journal</i> , 2008, 155, 274-283.	2.7	170
198	New antiplatelet therapies in development. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, S11-S15.	1.0	2

#	ARTICLE	IF	CITATIONS
199	'A threshold of platelet reactivity for ischaemic events?' and 'The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of care VerifyNow P2Y12 assay': reply. <i>European Heart Journal</i> , 2008, 29, 2187-2187.	2.2	0
200	Change We Can Believe In: The Hyper-Evolution of Percutaneous Coronary Intervention for Unprotected Left Main Disease With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 164-166.	3.9	3
201	Diesel Engine Turbocharger Rebuild and Experimental Testing. , 2007, , 485.		0
202	The effect of granulocyte colony stimulating factor on regional and global myocardial function in the porcine infarct model. <i>International Journal of Cardiology</i> , 2007, 116, 225-230.	1.7	13
203	Clopidogrel Desensitization After Drug-Eluting Stent Placement. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2039-2043.	2.8	45
204	Intracoronary radiation therapy for multi-drug resistant in-stent restenosis: Initial clinical experience. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 132-134.	1.7	12
205	Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial). <i>American Journal of Cardiology</i> , 2007, 100, 1099-1102.	1.6	19
206	Serial Angiographic Follow-Up of Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2006, 47, 871-877.	2.8	195
207	Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. <i>International Journal of Cardiology</i> , 2006, 111, 231-239.	1.7	175
208	Unprotected Left Main Coronary Intervention with Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2006, 19, S21-S26.	1.2	4
209	Rescue Percutaneous Coronary Intervention Early After Coronary Artery Bypass Grafting in the Drug-Eluting Stent Era. <i>American Journal of Cardiology</i> , 2006, 97, 789-791.	1.6	8
210	Differential Effects Between Intravenous and Targeted Renal Delivery of Fenoldopam on Renal Function and Blood Pressure in Patients Undergoing Cardiac Catheterization. <i>American Journal of Cardiology</i> , 2006, 97, 1076-1081.	1.6	40
211	Onset and Offset of Platelet Inhibition After High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers. <i>American Journal of Cardiology</i> , 2006, 98, 681-684.	1.6	130
212	Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure. <i>American Journal of Cardiology</i> , 2006, 98, 1345-1348.	1.6	30
213	Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 352-356.	1.7	8
214	Utility of three-dimensional reconstruction of coronary angiography to guide percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 69, 479-482.	1.7	63
215	A multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting. <i>Journal of Invasive Cardiology</i> , 2006, 18, 169-73.	0.4	2
216	Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 208-211.	1.7	28

#	ARTICLE	IF	CITATIONS
217	Mending the broken heart. Clinical Cardiology, 2003, 26, 449-450.	1.8	2
218	Stem Cell Repair of Infarcted Myocardium. Circulation, 2003, 108, 1139-1145.	1.6	149